[{"id":"315f3515-a4e3-4f7b-9cbb-e4e107970247","acronym":"","url":"https://clinicaltrials.gov/study/NCT06186076","created_at":"2023-12-29T19:18:43.407Z","updated_at":"2024-07-02T16:35:24.886Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients","source_id_and_acronym":"NCT06186076","lead_sponsor":"Therapex Co., Ltd","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TRX-221"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-12-29"},{"id":"a94c524c-ec96-4f51-b46e-9a20cc2c1fa2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05435248","created_at":"2022-06-28T15:54:09.835Z","updated_at":"2024-07-02T16:36:08.242Z","phase":"Phase 1/2","brief_title":"Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","source_id_and_acronym":"NCT05435248","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR C797S","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR C797S"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10375"],"overall_status":"Recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2022-06-28"}]